Park Avenue

Golden Minerals Announces Closing of US$4.2 Million Public Offering

Retrieved on: 
星期三, 十一月 8, 2023

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Key Points: 
  • H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
  • The gross proceeds from the offering were approximately $4.2 million, prior to deducting placement agent’s fees and other offering expenses payable by Golden.
  • Golden intends to use the net proceeds from the offering for working capital and other general corporate purposes.
  • The offering of the securities described above was made only by means of a prospectus forming part of the effective registration statement relating to the offering.

Ares Management Corporation Prices Offering of Senior Notes

Retrieved on: 
星期二, 十一月 7, 2023

Ares Management Corporation (the “Company”) (NYSE: ARES) today announced that it has priced an offering of $500,000,000 aggregate principal amount of its 6.375% Senior Notes due 2028 (the “notes”).

Key Points: 
  • Ares Management Corporation (the “Company”) (NYSE: ARES) today announced that it has priced an offering of $500,000,000 aggregate principal amount of its 6.375% Senior Notes due 2028 (the “notes”).
  • The notes will be fully and unconditionally guaranteed by Ares Holdings L.P., Ares Management LLC, Ares Investments Holdings LLC, Ares Finance Co. LLC, Ares Finance Co. II LLC, Ares Finance Co. III LLC and Ares Finance Co. IV LLC.
  • The offering is expected to close on November 10, 2023, subject to the satisfaction of customary closing conditions.
  • The net proceeds from the offering will be approximately $496.0 million, after deducting the underwriting discount but before offering expenses.

Avenue Therapeutics Announces Closing of $5.0 Million Public Offering

Retrieved on: 
星期四, 十一月 2, 2023

MIAMI, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the closing of its previously announced public offering of an aggregate of 16,633,400 units (or pre-funded units in lieu thereof) at a public offering price of $0.3006 per unit (inclusive of the pre-funded warrant exercise price of $0.0001 per share).

Key Points: 
  • MIAMI, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the closing of its previously announced public offering of an aggregate of 16,633,400 units (or pre-funded units in lieu thereof) at a public offering price of $0.3006 per unit (inclusive of the pre-funded warrant exercise price of $0.0001 per share).
  • The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are approximately $5.0 million.
  • Maxim Group LLC and Lake Street Capital Markets, LLC acted as placement agents for the offering.
  • The offering was made only by means of a prospectus which is a part of the effective registration statement.

NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant

Retrieved on: 
星期三, 十一月 1, 2023

The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.

Key Points: 
  • The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.
  • The closing of the Global Offering is not conditioned on the closing of the Concurrent Private Placement.
  • Leerink Partners, Guggenheim Securities and H.C. Wainwright & Co. are also acting as joint bookrunners for the Global Offering.
  • All securities to be sold in the Global Offering and the Concurrent Private Placement will be offered by the Company.

NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant

Retrieved on: 
星期三, 十一月 1, 2023

The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.

Key Points: 
  • The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.
  • The closing of the Global Offering is not conditioned on the closing of the Concurrent Private Placement.
  • Leerink Partners, Guggenheim Securities and H.C. Wainwright & Co. are also acting as joint bookrunners for the Global Offering.
  • All securities to be sold in the Global Offering and the Concurrent Private Placement will be offered by the Company.

POET Technologies Announces Public Offering of Common Shares and Warrants

Retrieved on: 
星期三, 十一月 1, 2023

Offering”).

Key Points: 
  • Offering”).
  • Concurrently, the Company has also commenced a non-brokered offering in Canada (the "LIFE Offering" and, together with the U.S. Offering, the "Offering").
  • The Offering consists of common shares of the Company and warrants to purchase common shares and is subject to market conditions.
  • In addition, POET intends to grant the underwriter a 45-day option to purchase up to an additional 15 percent of the number of common shares and/or warrants offered in the U.S. Offering.

BIO-key International Announces Closing of $3.75 Million Public Offering

Retrieved on: 
星期二, 十月 31, 2023

Each unit was sold at a public offering price of $0.175.

Key Points: 
  • Each unit was sold at a public offering price of $0.175.
  • The warrants will be immediately exercisable at a price of $0.175 per share and will expire five years from the date of issuance.
  • Gross proceeds, before deducting placement agent fees and estimated offering expenses, were approximately $3.75 million.
  • A final prospectus relating to the offering was filed with the SEC on October 31, 2023 and is available on the SEC’s website at http://www.sec.gov.

Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering

Retrieved on: 
星期二, 十月 31, 2023

MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the pricing of its public offering of an aggregate of 16,633,400 units at a public offering price of $0.3006 per unit.

Key Points: 
  • MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the pricing of its public offering of an aggregate of 16,633,400 units at a public offering price of $0.3006 per unit.
  • The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $5.0 million.
  • Maxim Group LLC and Lake Street Capital Markets, LLC are acting as placement agents for the offering.
  • The offering is being made only by means of a prospectus which is a part of the effective registration statement.

Worksport Announces Pricing of Approximately $4.7 Million Registered Direct Offering & Concurrent Private Placement

Retrieved on: 
星期二, 十月 31, 2023

In a concurrent private placement, the Company also agreed to issue and sell to the investor warrants to purchase up to 7,000,000 shares of common stock.

Key Points: 
  • In a concurrent private placement, the Company also agreed to issue and sell to the investor warrants to purchase up to 7,000,000 shares of common stock.
  • The combined effective offering price for each share of common stock (or pre-funded warrant in lieu thereof) and accompanying warrant is $1.34.
  • The gross proceeds to the Company from the registered direct offering and concurrent private placement are estimated to be approximately $4.7 million before deducting the placement agent's fees and other estimated offering expenses payable by the Company.
  • The offering is expected to close on or about November 2, 2023, subject to the satisfaction of customary closing conditions.

Draganfly Announces Closing of US$3.5 Million Underwritten Offering

Retrieved on: 
星期一, 十月 30, 2023

Los Angeles, CA., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions, and systems developer, is pleased to announce that it has closed its previously announced underwritten offering for gross proceeds of approximately US$3.5 million (the “Offering”), before deducting underwriting discounts and offering expenses.

Key Points: 
  • Los Angeles, CA., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions, and systems developer, is pleased to announce that it has closed its previously announced underwritten offering for gross proceeds of approximately US$3.5 million (the “Offering”), before deducting underwriting discounts and offering expenses.
  • Each Unit is comprised of one common share (a “Common Share”) and one common share purchase warrant (a “Warrant”).
  • Each Pre-Funded Unit is comprised of one pre-funded common share purchase warrant ‎‎(a “Pre-Funded Warrant”) and one Warrant.
  • The Offering was made pursuant to an effective shelf registration statement on Form F-10, as amended, (File No.